We have located links that may give you full text access.
Case Reports
English Abstract
Journal Article
[Use of bevacizumab as an additional strategy in angle closure glaucoma--case report].
Klinika Oczna 2010
We report the use of bevacizumab (Avastin) as an additional strategy in angle closure glaucoma based on the case of 47 years old male qualified to cataract removal as anti-glaucoma procedure, in whom we observed iris and lens neovascularization. As a first step we administered 1.25 mg of bevacizumab into the anterior chamber. Iris as well as lens neovasularization completely disappeared after 48 hours later. Finally after lens removal we achieved deeper anterior chamber, reduction and stabilization of intraocular pressure without necessity of administration hipotensive agents, and improvement of visual acuity.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app